Case 1: Newly Diagnosed CLL/SLL without del(17p)/TP53 mutation in a patient
Earn CME/CE while testing your knowledge. Try your skills at this challenging case in CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Case 2: Newly Diagnosed CLL/SLL with del(17p)/TP53 mutation
Earn CME/CE while testing your knowledge. Try your skills at this challenging case in CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Case 3: Relapsed CLL/SLL without del(17p)/TP53 mutation in a patient ≥65 years
Earn CME/CE while testing your knowledge. Try your skills at this challenging case in CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Case 4: Relapsed CLL/SLL with del(17p)/TP53 mutation and ibrutinib intolerance in a patient ≥65 years
Earn CME/CE while testing your knowledge. Try your skills at this challenging case in CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of targeted therapies as a preferred treatment approach for newly diagnosed chronic lymphocytic leukemia (CLL) has significantly transformed the treatment landscape of relapsed/refractory disease. Clinicians are challenged to remain up-to-date about the recent clinical advances that can help them make informed clinical decisions for individual patients to optimize clinical outcomes.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Minimal Residual Disease Assessment in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Is it Ready for Routine Clinical Practice?
There is a continuing need to educate clinicians about the current methods used for the detection of MRD and the prognostic significance of undetectable MRD in patients with CLL. This will also aid in the successful implementation of MRD testing when it becomes readily accessible for use in routine clinical setting.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates in the Treatment of Lymphoma
This presentation will help guide nurses in the use of novel agents, the timing of those agents, and the treatment when a patient has progressed after first-line therapy. New agents will be discussed, including administration information, side effects, and helpful patient education information for nursing.
Category
  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
Optimizing Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Educating clinicians about the recent clinical advances is essential since this will aid in making informed clinical decisions to optimize the treatment for relapsed/refractory CLL/SLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022
These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages